Nan. M Laird Harvey V. Fineberg Professor Emerita of Biostatistics Harvard University

# META-ANALYSIS: HETEROGENEITY CAN BE A GOOD THING

**META-ANALYSIS: DEFINITION** The statistical analysis of the findings of a collection of individual studies (Glass, 1976)

Differs from a review, uses a quantitative summary from each study for overall result.

## Background

- 1970's used extensively in social sciences
- Big questions----
  - Is psychotherapy effective?
  - What is the optimal class size for learning?
  - Are there teacher expectancy effects?
- The Placebo Effect (Beecher, 1955)

		Placebo		Dutionte	% Satis- factorily Relieved	
Condition	Study	Agent	Route *	No.	Dy a Placebo	
Severe post-	Keats, A. S., and Beecher, H. K.: J. Pharmacol.	Saline	1. V.	118	21	
o <b>perati</b> ve wound pain	& Exper. Therap. 100: 1-13, 1950 Beecher, H. K., and others: U. S. Armed Forces M. J. 2: 1960-1976, 1951	Saline	<b>S.</b> C.	29	31	
	Keats, A. S., and others: J. A. M. A. 147: 1761-	Saline	I. V.	34	26	
	Beecher and others (1953) <sup>3</sup>	Lactose	<b>P</b> . 0.	52 36 44 40	$\begin{array}{c} 40\\ 26\\ 34\\ 32 \end{array} \right\} \ 33$	
	Lasagna and others (1954) <sup>4</sup>	Saline	S. C.	14 20 15 21 15 15	50 37 53 40 40 15	
Cough	Gravenstein, J. S., and others: J. Appl. Physiol. 7: 119-139, 1954	Lactose	P. O.	22 22	36   40 43	
Drug-induced mood changes	Lasagna, L., and others: J. A. M. A. 157: 1006- 1020 (March 19) 1955	Isotonie sodium chloride	<b>S</b> . C.	Normal 20 "Post- 30 addicts"	30 30	
Pain from angina pectoris	Evans, W., and Hoyle, C.: Quart. J. Med. 2: 311-338, 1933	Sodium bicar- bonata	P. 0.	66	38	
	Travell, J., and others: Ann. New York Acad.	"Placebo"	P. O.	19	26	
	Sc. 52: 345-353, 1949 Greiner, T., and others: Am. J. Med. 9: 143- 155, 1950	Lactose	<b>P</b> . 0.	27	38	
Headache	Jellinek (1946)	Lactose	<b>P.</b> 0.	199	52	
Seasickness	Gay and Carliner (1949)	Lactose	<b>P</b> . <b>O</b> .	33	58	
Anxiety and tension	Wolf and Pinsky (1954) <sup>5</sup>	Lactose	<b>P.</b> 0.	31	30	
Experimental cough	Hillis (1952)	Isotonie sodium chloride	<b>S</b> . C.	Many ex- 1 periments	37	
Common cold	Diehl, H. S.: J. A. M. A. 101: 2042-2049 (Dec. 23)	Lactose	<b>P</b> . O.	Cold 110	35	
	1933			Subacute 48 chronic	35	
,				Total 1,082 A patients re	verage $35.2 \pm 2.2\%$	

#### TABLE 2.—Therapeutic Effectiveness of Placebos in Several Conditions

\* I. V., intravenous; S. C., subcutaneous; P. O., oral.

## Early Methods for Summarizing

### Largely descriptive reviews:

Report on studies and design of the studies, subject populations and subject characteristics, investigators, outcome measures, study follow-up, etc.

Meta- Analysis:

Use quantitative summary from each study. How to construct comparable effect sizes for combining results, how to weight studies.

Heterogeneity: Study results differ from one another. How to handle heterogeneity?



## Notation

Y = effect size for each study (risk difference, OR, or mean difference, regression coefficient)

s<sup>2</sup> is standard error of Y obtained from each study

Random Effects Model (Cochran, 1954)

$$Y_i = T_i + e_i$$

 $e_i$  is sampling variability for  $i^{\text{th}}$  study,  $\text{var}(e_i) = s_i^2$ 

 $E(T_i) = \mu$ 

$$\operatorname{var}(T_i) = \sigma^2$$

 $T_i$ , true study effects, are treated as random

#### Method of Analysis

$$E(Y_i) = \mu$$
  
Var(Y\_i) =  $\sigma^2 + s_i^2$ 

Decompose sample variance of  $Y_i$ 

$$\sum \left[ \left( Y_i - \bar{Y} \right)^2 / s_i^2 \right]$$

To obtain a 'Method of Moments' estimator of  $\sigma^2$ ,  $\hat{\sigma}^2$ .

Estimate  $\mu$  as

$$\widehat{\mu} = \sum \left[ Y_i / \left( \widehat{\sigma}^2 + s_i^2 \right) \right]$$
$$\text{var} \widehat{\mu} = \left[ \sum \left( \frac{1}{\widehat{\sigma}^2 + s_i^2} \right) \right]^{-1}$$

Assumptions,  $n_{c_i}$ ,  $n_{t_i}$  large, K large,  $T_i$  and  $e_i$  are independent

Random Effects Approach to Meta-Analysis

Advantages:

Provides a quantitative measure of how results differ, above and beyond sampling error.

Criticisms:

Studies should not be combined if effects differ.

 Major purpose of meta-analysis:
 Provide an overall summary, characterize and report variation in study results.

## Fixed Effects Model

- Set  $\sigma = o$ , analysis remains same:
- Estimate  $\mu$  with a weighted mean:  $w_i^f = 1/s_i^2$
- Weight driven by sample size
- Estimates of µ may be similar, but standard errors will be smaller under FE model:

$$w_i^r = 1/(s_i^2 + \sigma^2) < w_i^f$$
  
se<sup>r</sup> > se<sup>f</sup>

 RE confidence intervals and standard errors are smaller than corresponding FE estimates. Meta-Analysis in Genetic Association Studies

- Genetic Association Study: Usually a casecontrol study comparing genetic variants in cases and controls.
- Special issue: GWAS tests for millions of genetic variants, each test separately; primary interest is testing
- Effect sizes can be very small and typical significance level is 10<sup>-8</sup>
- Lot of interest in meta-analysis for increased power and replication
- Most individual studies are large (thousands of individuals, and number of studies is small)

### Obesity and the Insig2 Variant

- Insig2 variant found in one of first GWAS in Framingham Study Population
- Replicated in the original paper in 5 other cohorts and not replicated in one cohort
- Studies can be classified by design as: General population study, healthy population study, or comparative (case-control) study

**Table 3.** Summary of study results and meta-analysis. All values given are for a recessive model. NHS, Nurses Health Study; TDT, transmission disequilibrium test; PBAT, tools for FBATs.

Study	Design	Total genotyped	Obese	Non-obese	Test	Total number of families		P value
FHS	Family	694			PBAT	288		0.0030
Maywood	Family	866	361	505	PBAT dichotomous	342		0.0090
Maywood	Family	866			PBAT quantitative	342		0.0700
Essen children/adolescents	Trios	1104	368	-	TDT	368		0.0020
						Adjustments		
KORA	Cohort	3996			Linear regression	Sex, age		0.0080
NHS	Cohort	2726			Linear regression	Age		-
			Obese	Non-obese	Test	OR	95% CI	
KORA	Cohort	3996	935	3061	Logistic regression	1.32	1.06-1.65	0.0167
NHS	Cohort	2726	503	2223	Chi-squared test	0.81	0.58-1.13	-
American/Polish Caucasian	Case-control	2761	1835	926	Chi-squared test	1.40	1.08–1.78	0.0200
Maywood	Case-control	398	216	182	Fischer's exact test	2.36	_	0.0400
Pooled OR (all)		9881	3445	6426	2-tailed Mantel- Haenszel	1.22	1.05–1.42	0.0080

Meta-Analysis Designed to Explain Heterogeneity

- Lot of controversy about original paper
- Every clinical study measures height and weight and BMI
- Can measure one genetic variant easily
- Many, many 'studies' published on this association
- (Heid, et al, 2009) Collected results from 34 publications, 74,000 subjects to look at effect of study population

### Study Design

General Population Study (GP)
 Subjects included regardless of health status.

Healthy Populations (HP)
 Subjects deselected on basis of health conditions

Subjects selected on basis of obesity
 More powerful, and specific design

Study	OR [95% CI]	Weight [%]	OR [95% CI]
A Obesity analysis for GP ad	ult studies		
Cilento genetic		0.42	2.12 [0.67, 6.68]
SHARE Caucasian		- 0.44	1.11 [0.36, 3.42]
Kiel ageing		- 0.60	1.30 [0.49, 3.43]
Kiel genetics		1.43	0.67 [0.36, 1.26]
QFS		1.82	0.81 [0.46, 1.40]
FHS_UNREL		2.48	1.26 [0.79, 2.03]
EPIC Potsdam	<u>_</u>	4.58	1.04 [0.73, 1.47]
NFBC_1966	— <u>+</u>	5.60	0.99 [0.72, 1.36]
Czech_MONICA	+	7.04	1.20 [0.90, 1.59]
KORA S3		8.56	0.91 [0.70, 1.17]
DESIR		8.91	0.91 [0.71, 1.17]
EPIC_Norfolk	_ <del></del>	10.18	1.00 [0.79, 1.26]
SHIP	+	10.28	1.15 [0.91, 1.45]
CoLaus	_ <del></del>	10.56	1.09 [0.86, 1.37]
KORA_S4		10.69	1.33 [1.06, 1.67]
DECODE		16.41	1.29 [1.07, 1.55]
Pooled FE OR [95% CI]	▲	100.00	1.10 [1.02, 1.18]
Test for heterogeneity: $Chi^2 = 1$	$16.83, df = 15 (P = 0.33), I^2 = 10.9\%$		
Test for overall effect: $Z = 2.42$	(P = 0.02)		
<b>B</b> Obesity analysis for HP adu	ult studies		
HERITAGE_White	←=────	3.70	0.30 [0.10, 0.86]
NHS		12.03	0.81 [0.45, 1.46]
MRC_Ely		25.90	0.73 [0.49, 1.10]
SAPHIR		27.63	0.86 [0.58, 1.27]
NPHSII		30.74	0.89 [0.62, 1.29]
Pooled FE OR [95% CI]	-	100.00	0.80 [0.65, 0.98]
Test for heterogeneity: Chi <sup>2</sup> = 3	$3.93, df = 4 (P = 0.41), I^2 = 0\%$		
Test for overall effect: Z = 2.19	(P = 0.03)		
C Obesity analysis for OB ad	ult studies		
Essen obese		10.99	1.64 [0.94, 2.89]
OBENUTIC		16.21	1.09 [0.74, 1.60]
Utah_obese		17.18	0.78 [0.55, 1.12]
OB adult		17.22	0.85 [0.60, 1.21]
Berlin_obese		17.85	1.51 [1.08, 2.11]
American_Polish	<b> </b> −− <b>≡</b> −−	20.55	1.40 [1.08, 1.83]
Pooled RE OR [95% CI]		100.00	1.15 [0.90, 1.47]
Test for heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: Z = 1.14	I3.58, df = 5 (P = 0.02), I <sup>2</sup> = 63.2% (P = 0.25)		

### INSIG2 rs7566605 association with obesity Main meta-analysis results

	# cases/controls (# studies)	OR (p-value) fixed effect	OR (p-value) random effect	<u>I² (p-value)</u>
All	16,365/49,848 (27)	1.076 (0.023)	1.051 (0.268)	41.0 (0.015)
GP	9162/39,682 (16)	1.097 (0.015)	1.092 (0.035)	10.9 (0.329)
HP	1307/6333 (5)	0.796 (0.028)	0.796 (0.028)	0.0 (0.415)
OB	5896/3833 (6)	1.163 (0.018)	1.152 (0.253)	63.2 (0.018)

## Summary

- Heterogeneity does not preclude combining results. Important to report measure of heterogeneity, presence required caution in interpretation
- Heterogeneity can suggest important insights as to the nature of interventions, of populations, or both